Search PeptideClear
Peptides, vetted UK sellers, or GLP-1 clinics. Pick a tab below.
Try a quick search
We have not vetted that site yet.
PeptideClear can audit this source for you for free. Editorial verdict within 72 hours.
Got it. Editorial verdict within 72 hours.
We will email you a link to the published /retailer/[slug]/ profile once the audit lands.
While you wait, 3 already-vetted alternatives
Alternatives are matched to your stated goal. Click-throughs use affiliate links. No price difference for you. How we are funded.
Hormone therapy · UK 2026
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-06-02
UK hormone optimisation splits across several distinct routes. Testosterone replacement therapy (TRT) for men with clinically confirmed low testosterone. Bioidentical hormone replacement (BHRT) for peri- and post-menopausal women. HGH (somatropin) therapy under narrow UK licensed indication. GH secretagogue peptides under research-use-only framing. Low-dose female testosterone within British Menopause Society guidance. Thyroid hormone optimisation under POM rules. Each category sits under different UK regulation, has different evidence behind it, and answers a different clinical question. PeptideClear is a comparison and information service. We compare on price and evidence. We do not sell, prescribe, or take payment for placement.
Research peptide encyclopediaUK hormone optimisation covers six distinct categories. TRT (testosterone replacement therapy) for men with clinically confirmed low testosterone, available on the NHS for indicated hypogonadism and via private mens health clinics. BHRT (bioidentical hormone replacement) for peri- and post-menopausal women, with MHRA-licensed body-identical HRT as the mainstream route. HGH (somatropin) under a narrow UK licensed indication for genuine GH deficiency. GH secretagogue peptides (ipamorelin, sermorelin, tesamorelin) under research-use-only framing. Low-dose female testosterone within British Menopause Society guidance, currently off-licence. Thyroid hormone optimisation under POM. Each category is a separate clinical question with separate evidence. Your prescriber decides eligibility, drug and dose.
Each sits under different UK regulation and answers a different clinical question. The list is descriptive, not a ranking.
POM. UK private clinic route. NHS in some cases.
For men with clinically low testosterone confirmed on blood testing. Available on the NHS for clearly indicated hypogonadism. Most commercial UK demand is via private men's health clinics offering blood testing, GMC-prescriber consultation and ongoing oversight.
Mixed. Licensed and compounded formulations differ.
For peri- and post-menopausal women. UK MHRA-licensed bioidentical (body-identical) HRT (oestrogen, progesterone, testosterone) is available via GP and private menopause specialists. Compounded "BHRT" is a separate route covered by the British Menopause Society guidance.
POM. Tight UK indication.
Recombinant human growth hormone is a POM with a narrow UK indication (genuine GH deficiency confirmed via stimulation testing). Cosmetic or "anti-ageing" use sits outside licensed indication. Private clinics offering HGH sit in a tightly regulated space.
Research peptide tier. Not for human use.
Ipamorelin, sermorelin, tesamorelin and related compounds stimulate endogenous growth hormone release. Sold in the UK under "research use only, not for human use" framing. No UK marketing authorisation for human use.
Off-licence within BMS guidance.
Low-dose testosterone for post-menopausal women with persistent low sexual desire after adequate oestrogen replacement is supported by British Menopause Society guidance. Currently prescribed off-licence in the UK due to lack of a licensed female-dose product.
POM. NHS and private.
Levothyroxine for hypothyroidism is the standard NHS route. Private "thyroid optimisation" clinics may offer combination therapy (T4 plus T3) or NDT (natural desiccated thyroid) under private prescriber care. Each sits under POM regulation.
Hormone therapy is the canonical YMYL category. Dose depends on baseline blood tests, individual response, route of administration, age, weight, comorbidities and what a prescriber sees over time. A published "TRT starting dose" table on a comparison site would be misleading at best and dangerous at worst. We do not publish dose tables for any of the prescription routes covered here.
For research peptides marketed as GH secretagogues, the additional rule applies: research-use-only framing means no human-use protocols, no dosing, no cycle stacks. The encyclopedia entries for ipamorelin, sermorelin and tesamorelin cover history, mechanism, regulatory status and trial outcomes. They do not cover how to use the compounds in humans because that crosses the line MHRA enforcement targets.
What we will publish is the route map, the regulator-checkable trust signals for each clinic category, the evidence framing per route, and editorial commentary on the wider landscape.
TRT and HGH are POM under the Human Medicines Regulations 2012. Both can only be prescribed in the UK by a registered prescriber (most commonly GMC, in some cases independent prescriber pharmacist) after appropriate assessment. The clinic stack must include a GPhC-registered pharmacy for dispensing. NHS pathways exist for both within tightly defined indication; private routes exist alongside, offering faster access and bundled support.
Licensed BHRT (body-identical HRT) sits under the same POM regulation as TRT and HGH; the term "BHRT" in the UK context covers both licensed and compounded variants and the British Menopause Society has issued clear guidance distinguishing them. Compounded BHRT is a separate route with its own risks and editorial framing.
GH secretagogue peptides are the only category here that does not sit under POM. They are sold in the UK under research-use-only framing as research peptides. Once a retailer makes a human-use or medicinal claim, MHRA enforcement applies, exactly as it does to other research peptide compounds.
Also on PeptideClear
Cosmetic peptides
UK skincare with GHK-Cu, Matrixyl
If you also care about topical peptide skincare, the cosmetic peptides hub compares UK serums and creams on declared INCI position.
VisitCollagen
Marine, bovine, vegan compared
If you also care about ingestible collagen, the hub compares UK brands on type, sourcing, kDa and dose per serving.
VisitGLP-1 clinics
UK clinics ranked
If you also care about prescription GLP-1 routes, the clinics hub compares UK high-touch operators on GPhC, GMC and price.
VisitPeptideClear is a trading name of Best Business Loans Ltd, registered in England and Wales (company number 16833937). All services, operations and publications under the PeptideClear brand are delivered by Best Business Loans Ltd.
Registered in England and Wales. Company number 16833937. D‑U‑N‑S 234324824. ICO registered, reference ZC151816 (certificate, verify). Registered supplier on the UK Government's Find a Tender Service (FTS). Details publicly available via Companies House and OpenCorporates.
Operates under UK data protection and consumer standards. Aligns with UK GDPR, ISO 27001 and ISO 9001 principles. Working towards Cyber Essentials certification.
Primary domain peptideclear.co.uk. Business ownership, entity and services remain unchanged. Reviewed quarterly.